https://scholars.lib.ntu.edu.tw/handle/123456789/633531
標題: | Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer | 作者: | Slamon, Dennis J Fasching, Peter A Hurvitz, Sara Chia, Stephen Crown, John Martín, Miguel Barrios, Carlos H Bardia, Aditya Im, Seock-Ah Yardley, Denise A Untch, Michael CHIUN-SHENG HUANG et al., |
關鍵字: | CDK4/6 inhibitors; HR+/HER2– early breast cancer; NATALEE; adjuvant therapy; ribociclib | 公開日期: | 2023 | 卷: | 15 | 來源出版物: | Therapeutic advances in medical oncology | 摘要: | Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer. New Adjuvant Trial with Ribociclib [LEE011] (NATALEE) is a trial evaluating the efficacy and safety of adjuvant ribociclib plus endocrine therapy (ET) versus ET alone in patients with HR+/HER2- early nonmetastatic breast cancer (EBC). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633531 | ISSN: | 1758-8340 | DOI: | 10.1177/17588359231178125 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。